Warning: The NCBI web site requires JavaScript to function. more...
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.
Arthritis Res Ther. 2005;7(2):R333-42. Epub 2005 Jan 17.
Related citations
Factors associated with celecoxib and rofecoxib utilization.
Rawson NS, Nourjah P, Grosser SC, Graham DJ.
Ann Pharmacother. 2005 Apr;39(4):597-602. Epub 2005 Mar 8.
Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
Moride Y, Ducruet T, Boivin JF, Lavoie F, Rochon S.
Can J Clin Pharmacol. 2005 Summer;12(2):e201-11. Epub 2005 Jun 17.
Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC.
Drug Saf. 2008;31(2):143-58.
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503.
Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
Pharmacotherapy. 2009 Dec;29(12):1397-407.
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E, Nedjar H.
Rheumatology (Oxford). 2007 Mar;46(3):435-8. Epub 2007 Jan 25.
Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A.
Arch Intern Med. 2005 Jan 24;165(2):189-92.
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y, Velo GP, Sturkenboom M, Blin P, Moore N; CADEUS Team.
Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):891-900.
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
Brophy JM, Lévesque LE, Zhang B.
Heart. 2007 Feb;93(2):189-94. Epub 2006 Jul 18.
Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL.
Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31.
Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
J Med Assoc Thai. 2009 Dec;92 Suppl 6:S19-26.
Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
Arch Intern Med. 2005 May 9;165(9):978-84.
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
Am J Manag Care. 2002 Oct;8(15 Suppl):S392-400.
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Andersohn F, Schade R, Suissa S, Garbe E.
Stroke. 2006 Jul;37(7):1725-30. Epub 2006 May 25.
Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
Johnell K, Fastbom J.
Clin Drug Investig. 2008;28(11):687-95.
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Lévesque LE, Brophy JM, Zhang B.
CMAJ. 2006 May 23;174(11):1563-9. Epub 2006 May 2.
Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E, Toubouti Y, Hunsche E.
Rheumatology (Oxford). 2006 Jul;45(7):903-10. Epub 2006 Feb 3.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on